2014
DOI: 10.1002/alr.21426
|View full text |Cite
|
Sign up to set email alerts
|

RESOLVE: a randomized, controlled, blinded study of bioabsorbable steroid‐eluting sinus implants for in‐office treatment of recurrent sinonasal polyposis

Abstract: The symptomatic improvement and statistically significant reduction in polyp grade and ethmoid sinus obstruction supported the efficacy of the steroid-eluting implant for in-office treatment of CRS patient with recurrent polyposis after ESS. The study results demonstrated that the steroid-eluting implant represents a safe and effective alternative to current management for this patient population.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
57
0
1

Year Published

2014
2014
2019
2019

Publication Types

Select...
8

Relationship

5
3

Authors

Journals

citations
Cited by 59 publications
(60 citation statements)
references
References 25 publications
2
57
0
1
Order By: Relevance
“…Additional indications are on the horizon. 1323 Clinical experience with this device is relatively narrow at this point and evidence, though at a high level, is limited to short-term outcomes (Table X- r Harm: Potential for misplacement and local reaction. r Policy Level: The authors could not come to a consensus on the subject of corticosteroid-eluting stents.…”
Section: Xd6 Surgical Principles/techniques: Drug Eluting Packingmentioning
confidence: 99%
“…Additional indications are on the horizon. 1323 Clinical experience with this device is relatively narrow at this point and evidence, though at a high level, is limited to short-term outcomes (Table X- r Harm: Potential for misplacement and local reaction. r Policy Level: The authors could not come to a consensus on the subject of corticosteroid-eluting stents.…”
Section: Xd6 Surgical Principles/techniques: Drug Eluting Packingmentioning
confidence: 99%
“…When inserted at the time of sinus surgery, these stents significantly reduced postoperative surgical interventions by 51%, oral corticosteroid use by 40%, and frank nasal polyposis by 46% 79 after 1 month. Given these findings, a longer-lasting variant of Propel ™ is currently being evaluated in a FDA trial with initial results suggesting this stent can significantly improve polyp size and nasal symptoms 3 months following insertion 80 .…”
Section: Treatmentmentioning
confidence: 99%
“…With the beneficial development of office-placed bioabsorbable steroid-eluting implants for CRS, the effects of this focally delivered steroid on olfaction are yet to be determined. 52 …”
Section: Postoperative Considerations For Smell Lossmentioning
confidence: 99%